Identification and characterization of novel drugs that target the Influenza
Identification and characterization of novel drugs that target the Influenza
批准号:
9217553
负责人:
RICHARD J. WHITLEY
金额:
$104.47万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-03-01 至 2019-02-28
关键词:
AlabamaAmantadineAntiviral AgentsAntiviral TherapyBiological AssayBiological AvailabilityBirdsChemicalsChemistryComplementComplexCoupledDNA-Directed RNA PolymeraseDevelopmentDrug KineticsEffectivenessEpidemicEscape MutantExclusionExperimental DesignsFrequenciesGenetic TranscriptionGlycoproteinsGoalsHouse miceIn VitroIncidenceInfectionInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A virusInstructionInterferon InducersLeadLibrariesLife Cycle StagesModelingMutagenesisMutationNeuraminidase inhibitorPathogenicityPharmaceutical PreparationsPharmacotherapyPhenotypePolyadenylationPolymeraseProcessPropertyProteinsPublishingRNA replicationRNA-Directed RNA PolymeraseRNA-Protein InteractionResearchResistance developmentSpecificityStructureTherapeuticTriageUniversitiesViralViral PhysiologyVirusVirus DiseasesVirus Replicationbasedrug developmentdrug discoveryeffective therapyendonucleaseglobal healthhigh throughput screeningin vivoinfluenza epidemicinfluenza virus straininfluenzavirusinhibitor/antagonistmouse modelmutantnew therapeutic targetnovelnovel therapeuticsnucleoside inhibitorpandemic diseasereconstitutionresistance mutationscaffoldscreeningsmall moleculesmall molecule libraries
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The overall goal of this project is to identify new therapies that target influenza virus replication. The global health burden of annual influenza epidemics coupled with the emergence of highly pathogenic strains of influenza virus has highlighted the urgent need for new effective treatments A primary concern with the current drugs (amantadines and neuraminidase inhibitors) used to treat influenza is the development of resistance mutations that negate therapeutic benefit. Published evidence suggests that targeting the influenza virus RNA dependent RNA polymerase (RdRp) is a rational approach for antiviral therapy. The RdRp is responsible for a number of functions including 5'cap recognition, endonuclease activity, replication, transcription, and polyadenylation. Recently, cryo-EM reconstitution studies identified branchedribonucleoproteins (RNPs) structures as putative replication interhiediates and suggested a mechanism for viral replication by a second polymerase activity on the RNP template . The second polymerase activity is believed to be a function ofthe polymerase complex. Clearly, the RdRp provides multiple functional domains that could be targets for antiviral drug therapy. Previous studies showed that mutations in the conserved regions of PB1 subunit of the polymerase complex produce inactive RNA polymerase. We hypothesize that compounds that specifically target the polymerase complex might reduce the frequency of escape mutations, or promote escape mutants that are unfit for replication. We have recently identified potential hit compounds from previous HTS screens that significantly inhibit the influenza virus polymerase activity in an RdRp transient assay. These hit compounds were effective against three different strains of influenza viruses in CPE assays. We propose to characterize these compounds and use high-throughput screening (HTS) of novel small molecule libraries to identify anti-polymerase candidate compounds, chemically optimize them, and establish their effectiveness in an influenza mouse model.
\
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 4 - Influenza - UAB
-
批准号:10380669
-
项目类别:
-
资助金额:$93.75万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Antiviral Drug Discovery and Development Center (AD3C)
-
批准号:9888306
-
项目类别:
-
资助金额:$750.0万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Antiviral Drug Discovery and Development Center (AD3C)
-
批准号:10115578
-
项目类别:
-
资助金额:$750.0万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Project 4 - Influenza - UAB
-
批准号:10115602
-
项目类别:
-
资助金额:$88.85万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Administrative Core
-
批准号:10380661
-
项目类别:
-
资助金额:$93.75万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Project 4 - Influenza - UAB
-
批准号:10580026
-
项目类别:
-
资助金额:$87.22万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Administrative Core
-
批准号:10580017
-
项目类别:
-
资助金额:$18.23万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Antiviral Drug Discovery and Development Center (AD3C)
-
批准号:10380660
-
项目类别:
-
资助金额:$750.0万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Pilot and Feasibility Core
-
批准号:10465122
-
项目类别:
-
资助金额:$9.96万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Antiviral Drug Discovery and Development Center (AD3C)
-
批准号:10580015
-
项目类别:
-
资助金额:$750.0万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Pilot and Feasibility Core
-
批准号:10248361
-
项目类别:
-
资助金额:$12.37万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Administrative Core
-
批准号:10115588
-
项目类别:
-
资助金额:$18.96万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Pilot and Feasibility Core
-
批准号:10001434
-
项目类别:
-
资助金额:$7.72万
-
财政年份:2019
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Antiviral Drug Discovery and Development Center - Overall
-
批准号:8641766
-
项目类别:
-
资助金额:$627.07万
-
财政年份:2014
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Administrative Core
-
批准号:8299605
-
项目类别:
-
资助金额:$9.81万
-
财政年份:2011
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy
-
批准号:8299603
-
项目类别:
-
资助金额:$17.2万
-
财政年份:2011
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy
-
批准号:7747230
-
项目类别:
-
资助金额:$17.76万
-
财政年份:2009
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Administrative Core
-
批准号:7747238
-
项目类别:
-
资助金额:$10.12万
-
财政年份:2009
-
负责人:RICHARD J. WHITLEY
-
依托单位:
Development of Antiviral Screens and Animal Models
-
批准号:7652105
-
项目类别:
-
资助金额:$42.16万
-
财政年份:2008
-
负责人:RICHARD J. WHITLEY
-
依托单位:
BIOLOGIC CHARACTERIZATION OF ENGINEERED HSV FOR THERAPY OF BRAIN TUMORS
-
批准号:6502917
-
项目类别:
-
资助金额:$20.68万
-
财政年份:2001
-
负责人:RICHARD J. WHITLEY
-
依托单位:
海外基金